The combination of the Russian Sputnik V vaccine and the so-called “Oxford vaccine”, developed by the British University together with pharmaceutical company AstraZeneca, allegedly began as an exchange of explicit statements, but now became a reality is. However, the new product will face a testing phase, which will begin next week.
Economist Kirill Dmitryk, director of the Russian Direct Investment Fund – the body responsible for financing the study of the Moscow Gamelaya Center, which created Sputnik V – Saturday (2), said in an interview with the television channel Russia-1, That the work with the British is well advanced, and trials will begin on Tuesday (5).
Dimitriz said a clinical trial in conjunction with the two vaccines would take place in Ukraine, a country that has conflicting ties with Russia. When asked about this fact, the economist said that his country is “ready to cooperate with Ukraine in every way possible, as we believe this vaccine effort should not be influenced by politics”.
In the same interview, the director of the Gamalaya Center, Hangzhou Gintesburg, stated that the combination of Sputnik V and the “Oxford Vaccine” has at least two years of ability to generate immunity against SARS-COV-2 coronaviruses.